CMS Open Payments · Program Year 2024
Acera Surgical, Inc.
Acera Surgical, Inc. reported $863,722.47 across General Payments, Research, and Ownership to 4,195 physicians and teaching hospitals across 4,244 transactions.
- $863.7K Above-median payer
- All-tracks total
- 4,244 Top quartile volume
- Transactions
- 4,195 Top quartile reach
- Recipients
- +$270.8K
- General Payments vs PY2023
Acera Surgical, Inc. reported $863,722.47 across all CMS Open Payments tracks (General + Research + Ownership) to 4,195 physicians and teaching hospitals in Program Year 2024 - ranking #652 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $623,473.90, averaging $205.89 per recipient.
How Acera Surgical, Inc.'s $863.7K all-tracks total breaks down
Acera Surgical, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
48/100
Total payments
F
18/100
Transaction volume
F
41/100
Physician reach
F
42/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer acera-surgical-inc Acera Surgical, Inc.
$863.7K · #652/1,925 · 0.0% industry · PY2024
- TOT $863.7K
- RANK #652
- SHARE 0.0%
- TXN 4,244
- RCP 4,195
- CAT 7
- GEN $623.5K
- ΔGEN +$270.8K
- TOP1 17.9%
- PY 2024
Volume peers
Nearest volume peer: L&k Biomed Co. , Ltd. ($864.8K)
Acera Surgical, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Acera Surgical, Inc.'s CMS-reported General Payments increased by $270.8K (+76.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ACERA SURGICAL, INC.PY2023: ACERA SURGICAL, INC.PY2024: Acera Surgical, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $352,697.33
- PY2024
- $623,473.90
What the Data Shows for Acera Surgical, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Acera Surgical, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Debt Forgiveness" leads the 7-category general-payment breakdown below at $253.4K (40.6% of General Payments, 50 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Acera Surgical, Inc. made 7 types of general payments. "Debt Forgiveness" is the largest category at $253.4K, 40.6% of General Payments.
Acera Surgical, Inc. reports 7 general-payment categories - the top three are Debt Forgiveness (40.6%), Food and Beverage (39.9%), and Consulting Fee (11.5%). The remaining 4 categories make up 8.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Acera Surgical, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Debt Forgiveness | $253.4K | 50 | 40.6% |
| Food and Beverage | $248.6K | 3,995 | 39.9% |
| Consulting Fee | $71.9K | 43 | 11.5% |
| Travel and Lodging | $33.2K | 104 | 5.3% |
| Charitable Contribution | $10.0K | 1 | 1.6% |
| Grant | $4.0K | 1 | 0.6% |
| Education | $2.5K | 1 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $217,537.44 (34.9%) of $623,473.90 in this company's General Payments records across 2,923 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Acera Surgical, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Adrian Legaspi Sauter
$111,800.00 across 27 reported transactions
- 2
Vanitha Vasudevan
$42,250.00 across 4 reported transactions
- 3
Deviney A Rattigan
$27,620.00 across 1 reported transactions
- 4
Luis G Fernandez
$18,853.79 across 6 reported transactions
- 5
Katherine Bernadette Santosa
$17,013.65 across 28 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Acera Surgical, Inc. ranks #652 of 1,925 by total payments (top 34% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,348 of 1,838 by HHI (bottom 27% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Arthrex, Inc. : $104.3M total payments, HHI 439
- Uoc USA Inc : $460.8K total payments, HHI 437
- ZOLL Respicardia, Inc. : $325.9K total payments, HHI 435
- Vasorum USA Inc. : $12.3K total payments, HHI 435
- Hikma Pharmaceuticals USA : $501.2K total payments, HHI 435
- Butterfly Network, Inc. : $100.3K total payments, HHI 434
- Acera Surgical, Inc. (this company) : $623.5K total payments, HHI 432
- Sirtex Medical Inc : $2.5M total payments, HHI 432
- Cycle Pharmaceuticals Inc : $34.4K total payments, HHI 430
- Eli Lilly and Company : $8.0M total payments, HHI 429
- ASD Specialty Healthcare, LLC : $5.3K total payments, HHI 428
- Extremity Medical : $657.9K total payments, HHI 428
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Acera Surgical, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Acera Surgical, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Acera Surgical, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Sanara MedTech Inc.
Life Technologies Corporation
Jenavalve Technology, Inc.
Cornerstone Specialty Network LLC
Adagio Medical, Inc.
Put this to use
Acera Surgical, Inc. ranks #652 of 1,925 by all-tracks total payments, led by "Debt Forgiveness".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Debt Forgiveness" spend across every manufacturer, not just Acera Surgical, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.